The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma
Open accessAbstract
Malignant melanoma is a highly aggressive tumor of the pigment-producing cells in the skin with a rapidly increasing incidence and a poor prognosis for patients with advanced disease that is resistant to current therapeutic concepts. Therefore, the development of novel strategies for treating melanoma are of utmost importance. In melanoma, both the Ras-Raf-MEK-ERK (MAPK) and the PI3K-AKT (AKT) signaling pathways are constitutively activated through multiple mechanisms, and thus exert several key functions in melanoma development and progression. Conversely, several molecules known to play key roles in melanoma development and progression such as the adhesion molecules E-/N-cadherin, MelCAM and alphavbeta3 integrin are regulated by these pathways and/or activate the same. The results of the research to date indicate that in melanoma both the MAPK and the AKT signaling pathways may represent promising therapeutic targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Dan, H. C., Sun, M., Yang, L., Feldman, R. I., Sui, X.-M., Ou, C. C., Nellist, M., Yeung, R. S., Halley, D. J. J., Nicosia, S. V., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205838200 · Cited by 370
RetractedMutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma
Balch, C. M., Buzaid, A. C., Soong, S.-J., Atkins, M. B., Cascinelli, N., Coit, D. G., Fleming, I. D., Gershenwald, J. E., Houghton, A., Kirkwood, J. M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.16.3635 · Cited by 2,636
PI3K/Akt signalling pathway and cancer
Vara, J. Á. F., Casado, E., de Castro, J., Cejas, P., Belda-Iniesta, C., & González-Barón, M. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2003.07.007 · Cited by 2,443
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130
High frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730
The protein kinase B/Akt signalling pathway in human malignancy
Nicholson, K. M., & Anderson, N. G. (2002) · Cellular Signalling · doi:10.1016/s0898-6568(01)00271-6 · Cited by 1,639
Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., & Cantley, L. C. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00568-3 · Cited by 1,555
Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB
Kauffmann-Zeh, A., Rodriguez-Viciana, P., Ulrich, E., Gilbert, C., Coffer, P., Downward, J., & Evan, G. (1997) · Nature · doi:10.1038/385544a0 · Cited by 1,148
Rodriguez-Viciana, P., Warne, P. H., Khwaja, A., Marte, B. M., Pappin, D., Das, P., Waterfield, M. D., Ridley, A., & Downward, J. (1997) · Cell · doi:10.1016/s0092-8674(00)80226-3 · Cited by 1,061
Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation.
Pagès, G., Lenormand, P., L'Allemain, G., Chambard, J. C., Meloche, S., & Pouysségur, J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8319 · Cited by 984
Akt regulates growth by directly phosphorylating Tsc2
Potter, C. J., Pedraza, L. G., & Xu, T. (2002) · Nature Cell Biology · doi:10.1038/ncb840 · Cited by 959
HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation
Zhou, B. P., Liao, Y., Xia, W., Zou, Y., Spohn, B., & Hung, M.-C. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-973 · Cited by 951
PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest
Liang, J., Zubovitz, J., Petrocelli, T., Kotchetkov, R., Connor, M. K., Han, K., Lee, J.-H., Ciarallo, S., Catzavelos, C., Beniston, R., et al. (2002) · Nature Medicine · doi:10.1038/nm761 · Cited by 948
AKT plays a central role in tumorigenesis
Testa, J. R., & Bellacosa, A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211430998 · Cited by 944
Cobb, M. H. (1999) · Progress in Biophysics and Molecular Biology · doi:10.1016/s0079-6107(98)00056-x · Cited by 875
Tee, A. R., Fingar, D. C., Manning, B. D., Kwiatkowski, D. J., Cantley, L. C., & Blenis, J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202476899 · Cited by 827 · cited 1×
“These functions of the TSC1:TSC2 complex are mediated by inhibition of mammalian target of rapamycin (mTOR) (86, 87, 88, 89, 90).”
BackgroundMcGill, G. G., Horstmann, M., Widlund, H. R., Du, J., Motyckova, G., Nishimura, E. K., Lin, Y.-L., Ramaswamy, S., Avery, W., Ding, H.-F., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00762-6 · Cited by 760
PTEN: Life as a Tumor Suppressor
Simpson, L., & Parsons, R. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5130 · Cited by 679
Determinants of BRAF Mutations in Primary Melanomas
Maldonado, J. L., Fridlyand, J., Patel, H., Jain, A. N., Busam, K., Kageshita, T., Ono, T., Albertson, D. G., Pinkel, D., & Bastian, B. C. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg123 · Cited by 664 · cited 1×
“There is a high frequency of activating B-Raf mutations in melanomas arising on intermittently sun-exposed skin whereas melanomas arising in chronically sun-damaged skin and melanomas on skin relatively or completely unexposed to sun rarely harbor activating B-Raf mutations (11, 12).”
BackgroundSherr, C. J., & Weber, J. D. (2000) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)00038-6 · Cited by 654
Deregulated Akt3 Activity Promotes Development of Malignant Melanoma
Stahl, J. M., Sharma, A., Cheung, M., Zimmerman, M., Cheng, J. Q., Bosenberg, M. W., Kester, M., Sandirasegarane, L., & Robertson, G. P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1399 · Cited by 594
Get a ligand, get a life: integrins, signaling and cell survival
Stupack, D. G., & Cheresh, D. A. (2002) · Journal of Cell Science · doi:10.1242/jcs.00071 · Cited by 587
Bastian, B. C., LeBoit, P. E., Hamm, H., Bröcker, E.-B., & Pinkel, D. (1998) · PubMed · Cited by 513
N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells.
Li, G., Satyamoorthy, K., & Herlyn, M. (2001) · PubMed · Cited by 487
B-RAF is a therapeutic target in melanoma
Karasarides, M., Chiloeches, A., Hayward, R., Niculescu-Duvaz, D., Scanlon, I., Friedlos, F., Ogilvie, L., Hedley, D., Martin, J., Marshall, C. J., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207785 · Cited by 426
Satyamoorthy, K., Li, G., Gerrero, M. R., Brose, M. S., Volpe, P., Weber, B. L., Belle, P. A. V., Elder, D. E., & Herlyn, M. (2003) · PubMed · Cited by 426
Suppression of BRAF(V599E) in human melanoma abrogates transformation.
Hingorani, S. R., Jacobetz, M. A., Robertson, G. P., Herlyn, M., & Tuveson, D. A. (2003) · PubMed · Cited by 408
Hsu, M.-Y., Meier, F. E., Nesbit, M., Hsu, J.-Y., Van Belle, P., Elder, D. E., & Herlyn, M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65023-7 · Cited by 363
Self-citationA pivotal role for ERK in the oncogenic behaviour of malignant melanoma?
Smalley, K. S. M. (2003) · International Journal of Cancer · doi:10.1002/ijc.10978 · Cited by 325
Timing of cyclin D1 expression within G1 phase is controlled by Rho
Welsh, C. F., Roovers, K., Villanueva, J., Liu, Y., Schwartz, M. A., & Assoian, R. K. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-950 · Cited by 323
Dai, D. L., Martinka, M., & Li, G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.168 · Cited by 318
Mitogen-actived protein kinase activation is an early event in melanoma progression.
Cohen, C., Zavala-Pompa, Á., Sequeira, J., Shoji, M., Sexton, D. G., Cotsonis, G., Cerimele, F., Govindarajan, B., Macaron, N. C., & Arbiser, J. L. (2002) · PubMed · Cited by 275
Characteristics of cultured human melanocytes isolated from different stages of tumor progression.
Herlyn, M., Thurin, J., Balaban, G. B., Bennicelli, J. L., Herlyn, D., Elder, D. E., Bondi, E. E., Guerry, D., Nowell̀, P. C., & Clark, W. H. (1985) · PubMed · Cited by 274
Update on the incidence and mortality from melanoma in the United States
Hall, H. I., Miller, D. R., Rogers, J. D., & Bewerse, B. (1999) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(99)70562-1 · Cited by 272
The Ras-Raf-MEK-ERK Pathway in the Treatment of Cancer
Hilger, R. A., Scheulen, M. E., & Strumberg, D. (2002) · Oncology Research and Treatment · doi:10.1159/000068621 · Cited by 265
Dhawan, P., Singh, A. B., Ellis, D. L., & Richmond, A. J. (2002) · PubMed · Cited by 260
Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis.
Xie, S., Luca, M., Huang, S., Gutman, M., Reich, R., Johnson, J. P., & Bar‐Eli, M. (1997) · PubMed · Cited by 246
Microphthalmia Transcription Factor
King, R., Weilbaecher, K. N., McGill, G., Cooley, E., Mihm, M., & Fisher, D. E. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65172-3 · Cited by 242
Loss of PTEN promotes tumor development in malignant melanoma.
Stahl, J. M., Cheung, M., Sharma, A. K., Trivedi, N. R., Shanmugam, S., & Robertson, G. P. (2003) · PubMed · Cited by 241
Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival.
Petitclerc, É., Strömblad, S., Schalscha, T. V., Mitjans, F., Piulats, J., Montgomery, A. M. P., Cheresh, D. A., & Brooks, P. C. (1999) · PubMed · Cited by 237
Li, G., Schaider, H., Satyamoorthy, K., Hanakawa, Y., Hashimoto, K., & Herlyn, M. (2001) · Oncogene · doi:10.1038/sj.onc.1205034 · Cited by 212
Shifts in cadherin profiles between human normal melanocytes and melanomas.
Hsu, M., Wheelock, M. J., Johnson, K. R., & Herlyn, M. (1996) · PubMed · Cited by 212
Sumimoto, H., Miyagishi, M., Miyoshi, H., Yamagata, S., Shimizu, A., Taira, K., & Kawakami, Y. (2004) · Oncogene · doi:10.1038/sj.onc.1207812 · Cited by 194
Schuierer, M. M., Bataille, F., Hagan, S., Kolch, W., & Bosserhoff, A.-K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3861 · Cited by 193
Melanoma development and progression: a conspiracy between tumor and host
Hsu, M.-Y., Meier, F., & Herlyn, M. (2002) · Differentiation · doi:10.1046/j.1432-0436.2002.700906.x · Cited by 190
Self-citationAkt Mediates Ras Downregulation of RhoB, a Suppressor of Transformation, Invasion, and Metastasis
Jiang, K., Sun, J., Cheng, J., Djeu, J. Y., Wei, S., & Sebti, S. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.12.5565-5576.2004 · Cited by 182
Absence of BRAF mutations in UV-protected mucosal melanomas
Edwards, R. H., Ward, M. R., Wu, H., Medina, C. A., Brose, M. S., Volpe, P., Nussen-Lee, S., Haupt, H. M., Martin, A. M., Herlyn, M., et al. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2003.016667 · Cited by 178
Tumor progression in human malignant melanoma: Five stages defined by their antigenic phenotypes
Holzmann, B., Bröcker, E. B., Lehmann, J. M., Ruiter, D. J., Sorg, C., Riethmüller, G., & Johnson, J. P. (1987) · International Journal of Cancer · doi:10.1002/ijc.2910390410 · Cited by 170
Immune Evasion by Murine Melanoma Mediated through CC Chemokine Receptor-10
Murakami, T., Cardones, A. R., Finkelstein, S. E., Restifo, N. P., Klaunberg, B. A., Nestle, F. O., Castillo, S. S., Dennis, P. A., & Hwang, S. T. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030593 · Cited by 168
Zhang, X. D., Borrow, J. M., Zhang, X. Y., Nguyen, T., & Hersey, P. (2003) · Oncogene · doi:10.1038/sj.onc.1206427 · Cited by 163
Satyamoorthy, K., Li, G., Vaidya, B., Patel, D., & Herlyn, M. (2001) · PubMed · Cited by 159
Overexpression of Collagenase 1 (MMP-1) Is Mediated by the ERK Pathway in Invasive Melanoma Cells
Huntington, J. T., Shields, J. M., Der, C. J., Wyatt, C. A., Benbow, U., Slingluff, C. L., & Brinckerhoff, C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405102200 · Cited by 155
Smalley, K. S. M., & Eisen, T. G. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01726-9 · Cited by 152
Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma.
Mills, L., Tellez, C. S., Huang, S., Baker, C. H., McCarty, M. F., Green, L., Gudas, J. M., Feng, X., & Bar‐Eli, M. (2002) · PubMed · Cited by 152
Graells, J., Vinyals, A., Figueras, A., Llorens, A., Moreno, A., Marcoval, J., Gonzalez, F. J., & Fabra, À. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.23460.x · Cited by 146
Eisenmann, K. M., VanBrocklin, M. W., Staffend, N. A., Kitchen, S. M., & Koo, H.-M. (2003) · PubMed · Cited by 143
Ma, K., Ivanov, V. N., Dong, J., & Ronai, Z. A. (2003) · Oncogene · doi:10.1038/sj.onc.1206598 · Cited by 135
Hofmann, U. B., Westphal, J. R., van Kraats, A. A., Ruiter, D. J., & van Muijen, G. N. P. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000701)87:1<12::aid-ijc3>3.0.co;2-a · Cited by 132
Kandasamy, K., & Srivastava, R. K. (2002) · PubMed · Cited by 132
Woods, D. B., Cherwinski, H. M., Venetsanakos, E., Bhat, A., Gysin, S., Humbert, M., Bray, P. F., Saylor, V., & McMahon, M. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.9.3192-3205.2001 · Cited by 132
Yuan, X.-J., & Whang, Y. E. (2002) · Oncogene · doi:10.1038/sj/onc/1205054 · Cited by 132
The Brn-2 Transcription Factor Links Activated BRAF to Melanoma Proliferation
GOODALL, J. C., Wellbrock, C., Dexter, T. J., Roberts, K., Marais, R., & Goding, C. R. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.7.2923-2931.2004 · Cited by 126
Progression-related expression of β3 integrin in melanomas and nevi
Belle, P. A. V., Elenitsas, R., Satyamoorthy, K., Wolfe, J. T., Guerry, D., Schuchter, L. M., Belle, T. J. V., Albelda, S., Tahin, P., Herlyn, M., et al. (1999) · Human Pathology · doi:10.1016/s0046-8177(99)90202-2 · Cited by 123
Wang, Q., Wang, X., Hernandez, A., Hellmich, M. R., Gatalica, Z., & Evers, B. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206306200 · Cited by 109
Melanoma cell-cell interactions are mediated through heterophilic Mel-CAM/ligand adhesion.
Shih, I., Speicher, D. W., Hsu, M., Levine, E., & Herlyn, M. (1997) · PubMed · Cited by 101
Point mutations in the N-ras oncogene in malignant melanoma and congenital naevi
CARR, J., & Mackie, R. M. (1994) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1994.tb08460.x · Cited by 99
Reciprocal regulation of MelCAM and AKT in human melanoma
Li, G., Kalabis, J., Xu, X., Meier, F. E., Oka, M., Bogenrieder, T., & Herlyn, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206819 · Cited by 98
Self-citationInvolvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines
Tanami, H., Imoto, I., Hirasawa, A., Yuki, Y., Sonoda, I., Inoue, J., Yasui, K., Misawa-Furihata, A., Kawakami, Y., & Inazawa, J. (2004) · Oncogene · doi:10.1038/sj.onc.1208152 · Cited by 97
PI3K mediates protection against TRAIL-induced apoptosis in primary human melanocytes
Larribère, L., Khaled, M., Tartare‐Deckert, S., Buscà, R., Luciano, F., Bille, K., Valony, G., Eychène, A., Auberger, P., Ortonne, J. ‐., et al. (2004) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401475 · Cited by 93
Mechanisms of Cell-Cycle Arrest in Spitz Nevi with Constitutive Activation of the MAP-Kinase Pathway
Maldonado, J. L., Timmerman, L., Fridlyand, J., & Bastian, B. C. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63736-4 · Cited by 93
Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells
Kortylewski, M., Heinrich, P. C., Kauffmann, M.-E., Böhm, M., Mackiewicz, A. A., & Behrmann, I. (2001) · Biochemical Journal · doi:10.1042/bj3570297 · Cited by 86
Stewart, A. L., Mhashilkar, A. M., Yang, X. H., Ekmekçioglu, S., Saito, Y., Sieger, K., Schrock, R. D., Onishi, E., Swanson, X., Mumm, J. B., et al. (2002) · Molecular Medicine · doi:10.1007/bf03402025 · Cited by 84
Recent Advances in Melanoma Biology
Perlis, C., & Herlyn, M. (2004) · The Oncologist · doi:10.1634/theoncologist.9-2-182 · Cited by 79
Satyamoorthy, K., Muyrers, J. P. P., Meier, F. E., et al. (2001) · Oncogene · doi:10.1038/sj.onc.1204616 · Cited by 78
Self-citationBedogni, B., O’Neill, M. S., Welford, S. M., Bouley, D. M., Giaccia, A. J., Denko, N. C., & Powell, M. B. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3327 · Cited by 72
Alternate FGF2-ERK1/2 Signaling Pathways in Retinal Photoreceptor and Glial Cells in Vitro
Kinkl, N., Sahel, J., & Hicks, D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105256200 · Cited by 68
Tower, G. B., Coon, C. C., Benbow, U., Vincenti, M. P., & Brinckerhoff, C. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(01)00105-3 · Cited by 65
Bao, W., & Strömblad, S. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200404018 · Cited by 59
Sturm, R. A., Satyamoorthy, K., Meier, F., et al. (2002) · PubMed · Cited by 55
Self-citationvan Elsas, A., Zerp, S. F., van der Flier, S., Krüse-Wolters, M., Vacca, A., Ruiter, D. J., & Schrier, P. I. (1995) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-78771-3_5 · Cited by 54
Jetzt, A. E., Howe, J. A., Horn, M. T., Maxwell, E., Yin, Z., Johnson, D. E., & Kumar, C. C. (2003) · PubMed · Cited by 54
Interactions of Melanocytes and Melanoma Cells With the Microenvironment
Herlyn, M., & Shih, I. (1994) · Pigment Cell Research · doi:10.1111/j.1600-0749.1994.tb00025.x · Cited by 52
Denkert, C., Siegert, A., Leclere, A., Turzynski, A., & Hauptmann, S. (2002) · Clinical & Experimental Metastasis · doi:10.1023/a:1013857325012 · Cited by 50
Kanter‐Lewensohn, L. R., Dricu, A., Wang, M., Wejde, J., Kiessling, R. W., & Larsson, O. (1998) · Melanoma Research · doi:10.1097/00008390-199810000-00002 · Cited by 42
Smalley, K. S. M., & Eisen, T. G. (2002) · Melanoma Research · doi:10.1097/00008390-200206000-00001 · Cited by 34
Cited by
The mTOR Signalling Pathway in Human Cancer
Pópulo, H., Lopes, J. M., & Soares, P. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13021886 · Cited by 830
Stecca, B., Mas, C., Clement, V., Zbinden, M., Correa, R., Piguet, V., Beermann, F., & Ruiz i Altaba, A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700776104 · Cited by 530
Malignant melanoma: genetics and therapeutics in the genomic era
Chin, L., Garraway, L. A., & Fisher, D. E. (2006) · Genes & Development · doi:10.1101/gad.1437206 · Cited by 511
Many roads lead to oncogene-induced senescence
Courtois-Cox, S., Jones, S. L., & Cichowski, K. (2008) · Oncogene · doi:10.1038/sj.onc.1210950 · Cited by 397
From genes to drugs: targeted strategies for melanoma
Flaherty, K. T., Hodi, F. S., & Fisher, D. E. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3218 · Cited by 354
Metadata
- Authors
- Meier, F.
- Venue
- Frontiers in Bioscience
- Publisher
- IMR Press
- Published
- 2005
- Volume
- 10
- Issue
- 1-3
- Pages
- 2986
- ISSN
- 1093-4715 (ISSN-L)
- 1093-9946
- DOI
- 10.2741/1755
- OpenAlex
- W128422138
- Cited by
- 267
- References
- 90
- FWCI
- 5.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.